Farshid Dayyani
Chao Family Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Farshid Dayyani as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:04 UTC. Open this list on ClinicalTrials.gov
- Early Ph1NCT06824363 · ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a MuUniversity of California, Irvine · recruiting · Solid Tumor, Adult, Malignant Solid Tumor, Stomach Adenocarcinoma · principal investigator
- Ph1NCT05733689 · Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)University of California, Irvine · recruiting · Gastroesophageal Adenocarcinoma · principal investigator
- Ph1NCT04920032 · Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon AdenocarcinomasUniversity of California, Irvine · recruiting · Colon Adenocarcinoma, Colorectal Cancer · principal investigator
- Ph1NCT04868773 · Study of Cabozantinib Plus TAS102 in mCRC as Salvage TherapyUniversity of California, Irvine · completed · Colorectal Cancer, Colorectal Carcinoma, Metastatic Cancer · principal investigator
- Ph2NCT04472767 · Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaUniversity of California, Irvine · recruiting · Hepatocellular Carcinoma, HCC · principal investigator
- Ph2NCT04164979 · Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal AdenocarcinomaUniversity of California, Irvine · completed · Gastric Adenocarcinoma, GastroEsophageal Cancer · principal investigator
- Ph1NCT04074343 · TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal AdenocarcinomaUniversity of California, Irvine · completed · Gastric Adenocarcinoma, GastroEsophageal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:04 UTC. The ranking covers the 200 most relevant of 19 PubMed records, and a shared surname and initials can bring in a namesake. All 19 on PubMed
- Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.Lancet Gastroenterol Hepatol · 2024300 citationsRCR 38.0
- Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma.Clin Cancer Res · 2022116 citationsRCR 7.7
- Transcript profiling of CD16-positive monocytes reveals a unique molecular fingerprint.Eur J Immunol · 201277 citationsRCR 1.9
- Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).Cancer Chemother Pharmacol · 201455 citationsRCR 1.6
- First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.Eur J Cancer · 202144 citationsRCR 2.4
- Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma.J Hepatocell Carcinoma · 202124 citationsRCR 1.5
- A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.Clin Cancer Res · 202524 citationsRCR 4.4
- 16 citationsRCR 1.3
- Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.CPT Pharmacometrics Syst Pharmacol · 202112 citationsRCR 0.8
- Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors.Oncologist · 20259 citationsRCR 2.3